Published by Benjamin Chiou on 1st November 2023
(Sharecast News) - AstraZeneca is to invest in French biopharma group Cellectis to use its gene-editing technologies to develop next-gen therapeutics in areas like oncology, immunology and rare diseases.
URL: http://www.digitallook.com/dl/news/story/33876067/...